Head to Head Survey: Hyperfine (NASDAQ:HYPR) versus Olympus (OTCMKTS:OCPNY)

Olympus (OTCMKTS:OCPNY) and Hyperfine (NASDAQ:HYPR) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Insider & Institutional Ownership

0.0% of Olympus shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Olympus has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Valuation & Earnings

This table compares Olympus and Hyperfine”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olympus	$7.74 billion	2.99	$1.03 billion	$0.82	21.95
Hyperfine	$11.40 million	8.75	-$35.57 million	($0.38)	-2.47

Olympus has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Olympus and Hyperfine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olympus	0	0	1	0	3.00
Hyperfine	1	1	3	0	2.40

Hyperfine has a consensus target price of $2.03, indicating a potential upside of 116.29%. Given Hyperfine’s higher possible upside, analysts clearly believe Hyperfine is more favorable than Olympus.

Profitability

This table compares Olympus and Hyperfine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Olympus	13.80%	24.30%	9.30%
Hyperfine	-210.75%	-97.88%	-61.81%

Summary

Olympus beats Hyperfine on 8 of the 14 factors compared between the two stocks.

About Olympus

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.